Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Cancer Invest ; 28(5): 452-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19863344

ABSTRACT

It has been recently demonstrated that progranulin is overexpressed in ovarian cancer and that this protein is involved in the stimulation of cell proliferation, malignancy, and chemoresistance in ovarian cancer. The goal of the present study was to establish the differences in progranulin expression among normal, benign, and malignant ovarian tissues and to identify the signal transduction pathways activated by progranulin in an ovarian cancer cell line. Compared with benign tumors and normal ovarian tissue, progranulin mRNA and protein were overexpressed in malignant tumors. Survival analysis by the Kaplan-Meier method showed a correlation between high mRNA expression levels with poor survival outcome. Progranulin activated the MAPK-signaling pathway in NIH-OVCAR-3 cells. Progranulin expression may be potentially involved in the pathogenesis and malignant progression of ovarian cancer, and thus may represent a therapeutic target for this particular malignancy.


Subject(s)
Intercellular Signaling Peptides and Proteins/metabolism , Ovarian Neoplasms/metabolism , Ovary/metabolism , Adult , Aged , Aged, 80 and over , Apoptosis , Cell Line , Cell Line, Tumor , Cell Proliferation , Cell Survival , Female , Humans , Intercellular Signaling Peptides and Proteins/genetics , MAP Kinase Signaling System , Middle Aged , Ovarian Neoplasms/mortality , Progranulins
2.
Arch Med Res ; 32(6): 619-26, 2001.
Article in English | MEDLINE | ID: mdl-11750739

ABSTRACT

The development of the preimplantation mammalian embryo from a fertilized egg to a blastocyst capable of implanting in the uterus is a complex process. Cell division must be carefully programmed. The embryonic genome must be activated at the appropriate stage of development, and the pattern of gene expression must be carefully coordinated for the initiation of the correct program of differentiation. Cell fates must be chosen to establish specific cell types such as the inner cell mass and the trophectoderm, which give rise to the embryo proper and the placenta, respectively. This review summarizes recent findings concerning the influence of growth factors on the development of preimplantation mammalian embryos. Maternal factors secreted into the lumen of the female reproductive tract as well as substances synthesized by the developing embryo itself help to regulate this process. Studies of embryos in culture and investigations using homologous recombination to create embryos and animals null for specific genes have enabled the identification of several growth factors that appear essential for preimplantation mammalian embryo development. Some of the factors are required maternal factors; others are embryo-derived autocrine and paracrine factors. Studies using molecular biology are beginning to identify differences in the patterns of genes expressed by naturally derived embryos and those developing in culture. The knowledge gained from studies on growth factors, media, embryonic development, and gene expression should help improve culture conditions for embryos and will provide for safer outcomes from assisted reproductive procedures in human and animal clinics.


Subject(s)
Cleavage Stage, Ovum/physiology , Embryonic and Fetal Development/physiology , Gene Expression Regulation, Developmental/drug effects , Growth Substances/physiology , Animals , Cleavage Stage, Ovum/drug effects , Culture Media/pharmacology , Cytokines/physiology , Embryo Transfer , Embryonic and Fetal Development/drug effects , Female , Fertilization in Vitro , Forecasting , Growth Substances/classification , Growth Substances/pharmacology , Humans , Mammals/embryology , Mammals/physiology , Mice , Multigene Family , Pregnancy , Receptors, Cytokine/drug effects , Receptors, Cytokine/physiology , Receptors, Growth Factor/drug effects , Receptors, Growth Factor/physiology
3.
J Biol Chem ; 276(10): 7630-6, 2001 Mar 09.
Article in English | MEDLINE | ID: mdl-11115497

ABSTRACT

Spermatozoa are highly polarized cells with specific metabolic pathways compartmentalized in different regions. Previously, we hypothesized that glycolysis is organized in the fibrous sheath of the flagellum to provide ATP to dynein ATPases that generate motility and to protein kinases that regulate motility. Although a recent report suggested that glucose is not essential for murine sperm capacitation, we demonstrated that glucose (but not lactate or pyruvate) was necessary and sufficient to support the protein tyrosine phosphorylation events associated with capacitation. The effect of glucose on this signaling pathway was downstream of cAMP, and appeared to arise indirectly as a consequence of metabolism as opposed to a direct signaling effect. Moreover, the phosphorylation events were not affected by uncouplers of oxidative respiration, inhibitors of electron transfer, or by a lack of substrates for oxidative respiration in the medium. Further experiments aimed at identifying potential regulators of sperm glycolysis focused on a germ cell-specific isoform of hexokinase, HK1-SC, which localizes to the fibrous sheath. HK1-SC activity and biochemical localization did not change during sperm capacitation, suggesting that glycolysis in sperm is regulated either at the level of substrate availability or by downstream enzymes. These data support the hypothesis that ATP specifically produced by a compartmentalized glycolytic pathway in the principal piece of the flagellum, as opposed to ATP generated by mitochondria in the mid-piece, is strictly required for protein tyrosine phosphorylation events that take place during sperm capacitation. The relationship between these pathways suggests that spermatozoa offer a model system for the study of integration of compartmentalized metabolic and signaling pathways.


Subject(s)
Signal Transduction , Sperm Capacitation , Spermatozoa/metabolism , Adenosine Triphosphate/metabolism , Animals , Cell Differentiation , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Glucose/metabolism , Glycolysis , Hexokinase/chemistry , Immunoblotting , Kinetics , Lactic Acid/pharmacology , Male , Mice , Phosphorylation/drug effects , Protein Isoforms , Pyruvic Acid/pharmacology , Spectrophotometry , Sperm Capacitation/drug effects , Time Factors , Tyrosine/metabolism
4.
Dev Biol ; 217(2): 406-18, 2000 Jan 15.
Article in English | MEDLINE | ID: mdl-10625564

ABSTRACT

Preimplantation mammalian embryos in culture secrete autocrine growth factors into the surrounding medium that, in turn, stimulate the development of the embryos. The full complement of these factors is unknown. Since one hallmark of embryo development is the formation of an epithelium, the trophectoderm, we tested the hypothesis that one such embryo-derived growth factor is acrogranin (epithelin/granulin precursor), a factor that possesses growth-regulatory activities principally toward epithelial cells. We found that acrogranin mRNA was expressed in preimplantation mouse embryos with the transcript levels rising to their highest point in blastocysts, coincident with the appearance of the trophectoderm. Indirect immunofluorescence confocal microscopy of preimplantation mouse embryos at different developmental stages revealed that acrogranin immunostaining was most concentrated in the trophectoderm of blastocysts. Immunoblotting and immunoprecipitation experiments demonstrated that the embryos secreted acrogranin into the surrounding medium. To determine how altering the levels of acrogranin in the culture medium surrounding the embryos might affect embryonic growth and development, acrogranin protein levels in the culture medium were decreased with a function-blocking antibody or increased by adding the purified acrogranin to the medium. In both a concentration-dependent and a reversible manner, affinity-purified anti-acrogranin antibody significantly inhibited the development of eight-cell embryos to the blastocyst stage compared to controls (no added immunoglobulin or nonspecific IgG). Furthermore, embryo cell numbers were significantly decreased in the presence of the highest concentrations of acrogranin antibody compared to control embryos. Exogenous acrogranin added to cultures of eight-cell embryos accelerated the time for the onset of cavitation, as well as stimulating the rate of blastocoel expansion and increasing the number of trophectoderm cells compared to controls. These results indicate that acrogranin can regulate the appearance of the epithelium in the developing mouse blastocyst, the growth of the trophectoderm, and/or the function of the embryonic epithelium.


Subject(s)
Blastocyst/metabolism , Glycoproteins/metabolism , Growth Substances/metabolism , Intercellular Signaling Peptides and Proteins , Protein Precursors/metabolism , Animals , Autocrine Communication , Cell Differentiation , Cell Division , Cells, Cultured , Ectoderm , Epithelial Cells/cytology , Glycoproteins/genetics , Granulins , Growth Inhibitors/biosynthesis , Growth Substances/biosynthesis , Growth Substances/genetics , Mice , Progranulins , Protein Precursors/genetics , RNA, Messenger/analysis , Trophoblasts
5.
J Clin Endocrinol Metab ; 83(10): 3523-6, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9768658

ABSTRACT

In true hermaphroditism diverse phenotypes and karyotypes are found; there are no distinctive laboratory features that can distinguish it from other intersex disorders, thus the diagnosis is made by the histological findings. Existence of Leydig cells is demonstrated by testosterone levels above the female range; however, presence of ovarian tissue cannot be ascertained because of the absence of a reliable functional test. Unless appropriate biopsies are performed or the whole gonad is removed, there is a risk of not diagnosing true hermaphroditism. To find a reliable test that can differentiate patients with true hermaphroditism from those with other intersex disorders, we investigated the estradiol (E2) response to human menopausal gonadotropins (hMG) in infants with genital ambiguity. These results were correlated with the histological findings. Eleven infants with genital ambiguity and four with a high scrotal testis were stimulated every 12 h with 2 IU/kg hMG. If E2 rose above 80 pg/mL (cut-off point), the test was discontinued; if after 7 days E2 remained below 80 pg/mL, the hMG dose was doubled and stimulation extended for 7 additional days. In five patients in whom true hermaphroditism was later histologically demonstrated, E2 rose above 80 pg/mL. In two of them, ovarian tissue was removed and hMG stimulation repeated; no response above our cut-off point was observed during the second test. The maximal E2 response to hMG in the remaining 10 individuals was 43 pg/mL; after laparotomy or gonadal biopsies no ovarian tissue was found. The hMG stimulation test can be considered a reliable and safe dynamic procedure for demonstrating the presence or absence of ovarian tissue in infants with genital ambiguity.


Subject(s)
Disorders of Sex Development/blood , Disorders of Sex Development/diagnosis , Estradiol/blood , Menotropins , Adolescent , Child , Child, Preschool , Disorders of Sex Development/genetics , Disorders of Sex Development/pathology , Female , Follicle Stimulating Hormone/blood , Humans , Infant , Karyotyping , Luteinizing Hormone/blood , Male , Osmolar Concentration , Ovary/pathology , Testis/pathology
6.
Mol Hum Reprod ; 2(9): 643-50, 1996 Sep.
Article in English | MEDLINE | ID: mdl-9239677

ABSTRACT

In the present study we analysed the dynamics of serum human chorionic gonadotrophin (HCG) charge isoform distribution throughout normal gestation and characterized some of the biological features of the several HCG glycoforms present in the circulation of pregnant women. Blood samples were obtained from normal pregnant women at 10-11, 12-15, 23-26 and 35-38 weeks of gestation. The sera were fractionated by preparative chromatofocusing and the separated HCG isoforms were identified and quantified by radioimmunoassay. The in-vitro biological activity and the plasma half-life of the several circulating HCG isoforms were determined by conventional methods. HCG isoforms became less acidic as pregnancy advanced. In samples taken at 10-11 weeks of gestation, the most acidic HCG molecules (pH < 3.7) comprised > 80% of total HCG recovered after chromatofocusing; this proportion decreased to 58, 60 and 47% in samples taken from weeks 12.1 to 38.4 of gestation. Meanwhile, the relative proportion of less acidic isoforms recovered within pH values 6.49-4.50 increased at the end of the first trimester (12-15 weeks), remained constant until weeks 23-26 and then increased further by the end of the third trimester. Less acidic isoforms had higher in-vitro biological potency per immunological unit than the more acidic analogues. Regardless of the trimester of pregnancy, the plasma half-life of the highly acidic (elution pH < 3.7) isoforms varied from 84.4 to 150 min (116.3 +/- 23.0; mean +/- SD), whereas the corresponding half-life of mid-acidic (pH 4.25-5.31) and low-acidic (pH 5.74-6.50) HCG isoforms ranged from 31.0 to 115.3 (75.5 +/- 20.6) and 15.3 to 58.3 (41.2 +/- 14.3) min respectively (P < 0.01, highly acidic versus mid- and low-acidic analogues and mid-acidic versus least acidic isoforms). The overall data indicate that the human trophoblast is able to regulate the exact intensity, biochemical composition and duration of the gonadotrophic stimulus secreted during the course of normal gestation. They also suggest that the decrease and maintenance of low serum HCG concentrations during the second and third trimesters of gestation may be partially caused by changes in the carbohydrate structure of the HCG molecule.


Subject(s)
Chorionic Gonadotropin/blood , Chorionic Gonadotropin/chemistry , Pregnancy/blood , Adult , Animals , Female , Half-Life , Humans , Hydrogen-Ion Concentration , Isoelectric Focusing , Male , Molecular Structure , Pregnancy Trimester, First , Pregnancy Trimester, Second , Pregnancy Trimester, Third , Rats
7.
Arch Androl ; 37(1): 19-26, 1996.
Article in English | MEDLINE | ID: mdl-8827344

ABSTRACT

The 46,XX male syndrome is characterized by the presence of testicular development in subjects who lack a Y chromosome. The majority of patients have male external genitalia without ambiguity; however, 10-15% show diverse degrees of hypospadias. Testicular function is normal at birth but deteriorates thereafter. However, it has not been clarified why some cases exhibit genital ambiguity. This study examined 10 affected patients, including 4 prepubertal (< 1 year old) with hypospadias (1 glandular, 1 penile, and 2 penoscrotal). In all subjects, testicular function was evaluated by performing a stimulation with choriogonadotropin. In the postpubertal individuals, basal and poststimuli testosterone were below the reference values. Prepubertal patients had age-appropriate basal test-osterone concentrations. All responded to the choriogonadotropin challenge; however, the most significant response was observed in the patient with the glandular hypospadias, the second highest response was presented by the patient with the penile hypospadias, while both patients with the penoscrotal hypospadias had the poorest responses. These results suggest that the degree of genital ambiguity is correlated with the impairment in testosterone response to choriogonadotropin in early infancy, indicating a defect in testosterone production in XX males with genital ambiguity.


Subject(s)
Chorionic Gonadotropin/pharmacology , Chromosome Aberrations , Chromosome Disorders , Sex Chromosomes , Testis/drug effects , Adolescent , Adult , Child , Child, Preschool , Estradiol/metabolism , Follicle Stimulating Hormone/metabolism , Humans , Infant , Luteinizing Hormone/metabolism , Male , Phenotype , Testis/metabolism , Testosterone/metabolism
8.
J Clin Endocrinol Metab ; 80(5): 1647-56, 1995 May.
Article in English | MEDLINE | ID: mdl-7745013

ABSTRACT

In the present study we analyzed physiological changes in the relative distribution of FSH isoforms circulating under baseline conditions throughout the ovarian cycle as well as the forms discharged by GnRH stimulation from putative acutely releasable and reserve pituitary pools. Eight normally menstruating women underwent blood sampling on three occasions, once each during the presumptive early or midfollicular phase (FP), late follicular phase to midcycle (preovulatory phase; PO), and mid- to late luteal phase (LP) of the menstrual cycle. Blood samples were withdrawn at 10-min intervals for a total of 10 h before and after the iv administration of 10 and 90 micrograms GnRH. GnRH-stimulated FSH pulses were analyzed for secretory burst mass, secretory burst amplitude, integrated FSH concentrations, and endogenous FSH half-life by deconvolution. Serum FSH isoforms were separated by preparative chromatofocusing in 30 x 1-cm columns and identified by RIA of eluent fractions. The changes observed in serum FSH isoform distribution were then correlated with the corresponding secretory and clearance estimates of the released FSH molecules. In each phase of the menstrual cycle, a significant rise in serum FSH concentrations was observed after administration of the consecutive low and high dose GnRH pulses. The magnitude of the response in terms of secretory burst mass, secretory amplitude, and area of GnRH-induced FSH peaks was significantly higher during the PO. In all cycle phases, but particularly during the FP and PO, administration of the 90-micrograms GnRH dose elicited higher (1.4- to 1.7-fold) FSH secretory responses than the lower dose. Multiple parameter deconvolution of the GnRH-induced FSH pulses revealed that FSH molecules released in response to 10 micrograms GnRH at PO exhibited significantly (P < 0.01) shorter plasma half-lives (108 +/- 11 min) than those released during the follicular and luteal phases of the same menstrual cycles (apparent plasma half-life of FSH released at FP, 222 +/- 37 and 271 +/- 47 min for 10 and 90 micrograms GnRH-induced FSH pulses, respectively; LP, 244 +/- 41 and 198 +/- 40 min; P = NS, FP vs. LP) and in response to the high dose GnRH challenge at PO (276 +/- 40 min). Under all conditions studied, serum FSH charge isoforms were distributed along a pH range of 7.0 to less than 4.0.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Follicle Stimulating Hormone/blood , Gonadotropin-Releasing Hormone/pharmacology , Menstrual Cycle/blood , Adult , Female , Follicle Stimulating Hormone/chemistry , Humans , Isomerism
9.
Arch Med Res ; 26 Spec No: S219-30, 1995.
Article in English | MEDLINE | ID: mdl-8845653

ABSTRACT

In the present study, we analyzed the immunological and biological potencies as well as the molecular composition of urinary follicle-stimulating hormone (FSH) present in determined lots of regular and highly purified (HP) commercial preparations of urofollitropin in order to obtain additional insights on the particular type of gonadotropin signal received by the ovary during exogenously regulated ovarian stimulation. In both preparations, a high degree of FSH charge heterogeneity was detected as disclosed by chromatofocusing analysis (pH range 7.5 to < 4.0). Urinary FSH present in the HP compound was consistently more acidic and exhibited a longer survival in rat circulation than the regular formulation. Inter-batch variability for FSH heterogeneity and in vitro bioactivity was higher in the partially purified preparation than in the HP analog. In the regular preparation, the amount of immunoreactive and bioactive FSH per ampule was two times higher than that present in the HP preparation; the resultant in vitro B/I ratios were similar. Although both urinary FSH preparations showed detectable amounts of immunoreactive and bioactive luteinizing hormone and choriogonadotropin hormone material, the degree of activity present in the less purified formulation was considerably higher than that shown by the HP analog. When the capability of each urinary FSH preparation to induce ovarian tissue-type plasminogen activator enzyme activity in hypophysectomized rats was determined, both formulations exhibited similar potencies despite the existing differences in plasma clearance rate and charge distribution profile. The present study indicates that the isoform composition of urinary FSH in the two commercial preparations analyzed differs according to the degree of purity of the formulation. More FSH material is needed in the partially purified FSH preparation to induce biological effects similar in magnitude to those exhibited by the highly purified analog. The possible impact of these variations in the molecular composition of the FSH signal on other biological functions of the ovary during the course of exogenously controlled follicular growth and maturation still remains to be ascertained.


Subject(s)
Follicle Stimulating Hormone/pharmacology , Ovarian Follicle/drug effects , Ovary/drug effects , Signal Transduction/drug effects , Animals , Female , Follicle Stimulating Hormone/chemistry , Follicle Stimulating Hormone/immunology , Follicle Stimulating Hormone/metabolism , Humans , Male , Ovarian Follicle/growth & development , Rats , Rats, Wistar
10.
J Clin Endocrinol Metab ; 78(4): 890-7, 1994 Apr.
Article in English | MEDLINE | ID: mdl-8157717

ABSTRACT

In the present study, we examined the regulation of 24-h serum immunoreactive levels, in vitro biological to immunological (B/I) ratio, and median charge of circulating CG at the end of the first, second, and third trimesters of human gestation. Seven pregnant women were prospectively studied at 12-15, 23-26, and 35-38 weeks of gestation. Blood was sampled every 20 min over a 24-h period, and serum CG concentrations were determined by RIA. Pulse detection and analysis of the 24-h rhythm of serum immunoreactive CG concentrations were carried out by the program Cluster and cosine curve fitting, respectively. The in vitro biological activity of circulating CG was determined by the mouse Leydig cell-testosterone production bioassay, and the median charge of its isoforms was determined by zone electrophoresis in agarose suspension. The immunoreactive levels of CG present at the end of each trimester of gestation fluctuated over a 24-h period; such variability exceeded that of the within-assay coefficient of variation of the CG RIA and could be resolved into a series of CG peaks and valleys. Although no trend in the number of peaks or valleys was systematically found in relation to gestational age, comparisons between the amplitude and area of the CG peaks revealed that these pulse parameters were significantly higher at 12-15 weeks than at 23-26 and 35-38 weeks of gestation. Cosine fits for 24-h rhythms revealed the existence of significant nyctohemeral profiles of serum CG levels in all women studied at 12-15 weeks, in four subjects at 23-26 weeks, and in six women at 35-38 weeks gestation. The time of acrophase was highly homogeneous only between 12-15 weeks of gestation, occurring between 1057-1452 h in six of the women. The in vitro B/I ratio of CG contained in serum pools from 12-15 weeks was significantly (P < 0.05) higher than that exhibited by CG during later gestational periods (B/I ratio at the end of first trimester, 1.14 +/- 0.14; second trimester, 0.87 +/- 0.22; third trimester, 0.79 +/- 0.12). hCG isoforms at 12-15 weeks were more negatively charged than those circulating at 23-26 and 35-38 weeks of gestation. There were no significant differences between the B/I ratio and the median charge of CG molecules from the second and third trimesters. We conclude that serial serum concentrations of CG throughout pregnancy show significant amplitude-modulated pulsatile release and nyctohemeral variations.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Chorionic Gonadotropin/metabolism , Chorionic Gonadotropin/physiology , Circadian Rhythm/physiology , Pregnancy/immunology , Pregnancy/metabolism , Adult , Chorionic Gonadotropin/immunology , Female , Humans , Leydig Cells/metabolism , Male , Pregnancy Trimester, First , Pregnancy Trimester, Second , Pregnancy Trimester, Third , Radioimmunoassay , Testosterone/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...